Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Share-based Compensation of $16.0 million for Q1 2026, up 12.46% year-over-year from $14.2 million in Q1 2025, and up 135.22% quarter-over-quarter from -$45.5 million in Q4 2025.
Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Share-based Compensation for 8 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 12.46% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $205000.0 (down 90.95% YoY), while the FY2025 annual figure was $63.4 million, down 7.31% from the prior year.
- Share-based Compensation grew to $16.0 million in Q1 2026 per KYMR's latest filing, from -$45.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $73.5 million in Q3 2025 and bottomed at -$45.5 million in Q4 2025.
- Historically, Share-based Compensation has averaged $9.0 million across 5 years, with a median of $11.4 million in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 478.17% — and 2025, when it surged 393.16%.
- Kymera Therapeutics' Share-based Compensation stood at $9.1 million in 2022, then gained by 20.07% to $10.9 million in 2023, then tumbled by 478.17% to -$41.2 million in 2024, then fell by 10.28% to -$45.5 million in 2025, then surged by 135.22% to $16.0 million in 2026.
- Business Quant data shows KYMR's Share-based Compensation at $16.0 million in Q1 2026, -$45.5 million in Q4 2025, and $73.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 18.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.94 Mn |
| Jun 30, 2026 | 18.94 Mn |
| Mar 31, 2026 | 16.01 Mn |
| Mar 31, 2026 | 16.01 Mn |
| Dec 31, 2025 | -45.45 Mn |
| Dec 31, 2025 | -45.45 Mn |
| Sep 30, 2025 | 73.50 Mn |
| Sep 30, 2025 | 73.50 Mn |
| Jun 30, 2025 | 15.42 Mn |
| Jun 30, 2025 | 15.42 Mn |
| Mar 31, 2025 | 14.23 Mn |
| Mar 31, 2025 | 14.23 Mn |
| Dec 31, 2024 | -41.21 Mn |
| Dec 31, 2024 | -41.21 Mn |
| Sep 30, 2024 | 14.90 Mn |
| Sep 30, 2024 | 14.90 Mn |
| Jun 30, 2024 | 14.34 Mn |
| Jun 30, 2024 | 14.34 Mn |
| Mar 31, 2024 | 11.97 Mn |
| Mar 31, 2024 | 11.97 Mn |